Image Source: Unsplash

The munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 6 constituents in the munKNEE Pure-Play Marijuana Drug Stocks Index sub-category and 12 in the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index. Which index outperformed in November and which constituents contributed to that performance? This article has the answer. Here are the details:

100 clinical-stage psychedelic drug stocks now trade on North American stock exchanges. 60 of the stocks research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them) and 40 research the treatment of illnesses based on the use of THC marijuana (read Marijuana Drug Stocks: All You Need To Know). The criteria for inclusion in the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index is that its constituents have market capitalizations in excess of $40M (only six have market caps below $100M) and only 18 of those 100 psychedelic drug stocks meet that criteria.

The Pure-Play Marijuana Drug Stocks Index

The 6 marijuana-based clinical-stage stocks:

• were DOWN -13.2% in November 
• are now DOWN -26.9% since the end of June
• with 3 trading below $1/share; another 2 trading for less than $2/share  and 1 trading for $3.46/share with an average price of $1.35/share (Currency amounts are in U.S. dollars. Go here to convert to another currency) and
• with an average market capitalization of $104M currently.

All 6 constituents changed in price by +/-5% in November and their performances are presented below in descending order (with their performances since the end of June in brackets). 

1. Revive (RVVTF): UP +5.1%; (DOWN -16.3%)
2. Tetra Bio (TBPMF): DOWN -5.6%; (DOWN -37.0%)
3. Allied (ALID): DOWN -9.6%; (UP +72.5%)
4. Zynerba (ZYNE): DOWN -9.7%; (UP +4.8%) 
5. Corbus (CRBP): DOWN -14.0%; (DOWN -52.0%)
6. Enveric (ENVB): DOWN -26.1%; (DOWN -33.8%)

The Pure-Play Psychedelic Compounds-Based Drug Stocks Index

The 12 psychedelic compound-based clinical-stage stocks are divided into 2 groups based on their market capitalizations.

The 9 constituents with market caps below $1B: 

• were DOWN -21.2% in November, 
• are now DOWN -29.9% since the end of June
• with 4 trading below $1/share; another 3 trading for less than $2/share, and 2 trading at $2.31 and $4.01 with an average price of $1.39/share (Currency amounts are in U.S. dollars. Go here to convert to another currency) with 
• an average market capitalization of $206M.

8 of the 9 constituents went DOWN dramatically in price in November and their performances are presented below in descending order (with their performances since the end of June in brackets). 

1. Awakn (AWKNF): UP +0.4%; (UP +6%) Read: Awakn Life Sciences: Wake Up To The Huge Potential
2. Numinus (LKYSF): DOWN -19.0%; (DOWN -44.0%)
3. Seelos (SEEL): DOWN -19.9%; (UP +9.5%)
4. Mind Medicine (MNMD): DOWN -21.4%; (DOWN -35.1%)
5. Cybin (CYBN): DOWN -21.4%; (DOWN -2.0%)
6. Small Pharma (DMTTF): DOWN -27.3%; (DOWN -12.5%)
7. Field Trip (FTRP):  DOWN -29.2%; (UP +23.4%)
8. Red Light (TRUFF): DOWN -33.3%; (DOWN -60.0%) and 
9. Mydecine (MYCOF): DOWN -37.5%; (DOWN -57.1%).

The 3 constituents with market caps above $1B:

• were DOWN -15.2% in November, 
• are now DOWN -9.0% since the end of June
• with one trading at $10.98/share; another trading at $25.48/share and the other trading at $33.20/share with an average price of $23.22/share (Currency amounts are in U.S. dollars. Go here to convert to another currency) with 
• an average market capitalization of $1.53B and they
• also did poorly in November (with their performances since the end of June in brackets.), as follows:

1. GH Resources ((GHRS)): UP +0.7%; (UP +20.0%)
2. Compass Pathways (CMPS): DOWN -21.3%; (DOWN -30.3%) and
3. Atai (ATAI): DOWN -24.7%; DOWN -39.1%)

On average, the 12 constituents in the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index:

• were DOWN -16.1% in November
• are now DOWN -12.9% since the end of June
• and now have an average market capitalization of $381.7M.

In Summary

In answer to the opening question as to which Index out-performed in November, the answer is:

• the munKNEE Pure-Play Marijuana Drug Stocks Index went DOWN -13.2% in November and is now DOWN -26.9% since the end of June,
• the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index went DOWN -16.1% in November but is now DOWN -12.9% since the end of June and the combined total of 18 constituents in
• the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index went DOWN -15.9% in November and are now DOWN -14.4% since the end of June.

As a point of comparison, the non-tradable Psychedelic Market Leaders Index of 30 stocks, with an average market cap of $226.5M, was DOWN -19.7% in November while the non-tradable Psychedelic Invest Index, which tracks the performance of ALL 60 stocks in the sector (an average market capitalization of just $124.4M), was DOWN -16.8%.

You are encouraged to click on the hyperlinked symbols above of those stocks you are interested in, review their latest financial statements and commentary as found in the TalkMarkets data there and visit the company websites.